1631 related articles for article (PubMed ID: 19765436)
1. Conversion to sirolimus for chronic allograft nephropathy and calcineurin inhibitor toxicity and the adverse effects of sirolimus after conversion.
Sayin B; Karakayali H; Colak T; Sevmis S; Pehlivan S; Demirhan B; Haberal M
Transplant Proc; 2009 Sep; 41(7):2789-93. PubMed ID: 19765436
[TBL] [Abstract][Full Text] [Related]
2. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
3. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Jun; 10(4):474-8. PubMed ID: 16712606
[TBL] [Abstract][Full Text] [Related]
4. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients.
Boratyńska M; Banasik M; Watorek E; Falkiewicz K; Patrzałek D; Szyber P; Klinger M
Transplant Proc; 2006; 38(1):101-4. PubMed ID: 16504675
[TBL] [Abstract][Full Text] [Related]
5. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
Sundberg AK; Rohr MS; Hartmann EL; Adams PL; Stratta RJ
Clin Transplant; 2004; 18 Suppl 12():61-6. PubMed ID: 15217410
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of proteinuria in renal transplant recipients switching to rapamycin for chronic allograft dysfunction.
Gutiérrez MJ; González E; Andrés A; Morales JM
Transplant Proc; 2009; 41(6):2348-50. PubMed ID: 19715916
[TBL] [Abstract][Full Text] [Related]
7. Proteinuria after conversion to sirolimus in renal transplant recipients.
Sahin GM; Sahin S; Kantarci G; Ergin H
Transplant Proc; 2006 Dec; 38(10):3473-5. PubMed ID: 17175308
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus allows preservation of renal function in kidney and kidney-pancreas allograft recipients.
Laham G; Sleiman S; Soler Pujol G; Diaz C; Dávalos M; Vilches A
Transplant Proc; 2010; 42(1):309-13. PubMed ID: 20172338
[TBL] [Abstract][Full Text] [Related]
9. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction.
Ruiz JC; Campistol JM; Sánchez-Fructuoso A; Rivera C; Oliver J; Ramos D; Campos B; Arias M; Diekmann F
Nephrol Dial Transplant; 2006 Nov; 21(11):3252-7. PubMed ID: 16954170
[TBL] [Abstract][Full Text] [Related]
10. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus.
Fairbanks KD; Eustace JA; Fine D; Thuluvath PJ
Liver Transpl; 2003 Oct; 9(10):1079-85. PubMed ID: 14526403
[TBL] [Abstract][Full Text] [Related]
11. Conversion from calcineurin inhibitor to sirolimus in pediatric chronic allograft nephropathy.
Falger JC; Mueller T; Arbeiter K; Boehm M; Regele H; Balzar E; Aufricht C
Pediatr Transplant; 2006 Aug; 10(5):565-9. PubMed ID: 16856992
[TBL] [Abstract][Full Text] [Related]
12. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
Uslu A; Töz H; Sen S; Alkan FT; Nart A; Aykas A; Doğan M; Postaci H; Sahin T; Simşek C
Transplant Proc; 2009 Mar; 41(2):756-63. PubMed ID: 19328973
[TBL] [Abstract][Full Text] [Related]
13. Conversion to sirolimus in renal transplant recipients: a single-center experience.
Yelken B; Caliskan Y; Ozkan O; Gorgulu N; Yazici H; Turkmen A; Sever MS
Artif Organs; 2010 Aug; 34(8):E230-7. PubMed ID: 20618227
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus conversion experience in a single center.
Wang HH; Huang JY; Chu SH; Chiang YJ; Liu KL; Lai PC
Transplant Proc; 2008 Sep; 40(7):2209-10. PubMed ID: 18790194
[TBL] [Abstract][Full Text] [Related]
15. Early sirolimus therapy in renal transplant recipients at high risk: is it justified?
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Al-Waheeb S; Hasaneen H; Awadain WH; Nawas KM; El-Sayed A; Said T; Nair MP; Nampoory MR
Transplant Proc; 2009 Sep; 41(7):2784-8. PubMed ID: 19765435
[TBL] [Abstract][Full Text] [Related]
16. Sirolimus in chronic allograft nephropathy.
Wu MJ; Shu KH; Cheng CH; Chen CH
Transplant Proc; 2004 Sep; 36(7):2053-5. PubMed ID: 15518743
[TBL] [Abstract][Full Text] [Related]
17. Evolution of proteinuria after conversion from calcineurin inhibitors (CNI) to sirolimus (SRL) in renal transplant patients: a multicenter study.
Ruiz JC; Diekmann F; Campistol JM; Sanchez-Fructuoso A; Rivera C; Oliver J; Fernandez-Fresnedo G; Arias M
Transplant Proc; 2005 Nov; 37(9):3833-5. PubMed ID: 16386555
[TBL] [Abstract][Full Text] [Related]
18. Sirolimus as an alternative to anticalcineurin therapy in heart transplantation: experience of a single center.
Fernandez-Valls M; Gonzalez-Vilchez F; de Prada JA; Ruano J; Ruisanchez C; Martin-Duran R
Transplant Proc; 2005 Nov; 37(9):4021-3. PubMed ID: 16386615
[TBL] [Abstract][Full Text] [Related]
19. Recovery of renal function in heart transplantation patients after conversion from a calcineurin inhibitor-based therapy to sirolimus.
Ayub-Ferreira SM; Avila MS; Feitosa FS; Souza GE; Mangini S; Marcondes-Braga FG; Issa VS; Bacal F; Chizzola PR; Cruz FD; Bocchi EA
Transplant Proc; 2010 Mar; 42(2):542-4. PubMed ID: 20304188
[TBL] [Abstract][Full Text] [Related]
20. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
Uslu A; Nart A; Taşli FA; Postaci H; Aykas A; Doğan M; Sahin T
Nephrology (Carlton); 2008 Feb; 13(1):80-6. PubMed ID: 18199109
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
